{
  "ticker": "CAH",
  "cik": "0000721371",
  "company_name": "CARDINAL HEALTH INC",
  "filing_date": "2025-08-12",
  "item1_summary": " Cardinal Health’s IT risk governance process includes multiple levels of escalation from IT Risk Advisory Board to an executive-level committee to help address cybersecurity risks at an enterprise level . The Board has delegated to the Audit Committee primary responsibility for overseeing cybersecurity and other major technology-related risks and our actions to monitor and mitigate such risks . The Audit Committee receives at least quarterly updates from the CISO and CIO .\n At June 30, 2025, the Pharma segment operated one national logistics center and a number of primary pharmaceutical and specialty distribution facilities . The GMPD segment operated medical-surgical distribution, assembly, manufacturing, and other operating facilities in the United States . The legal proceedings described in  the \"Notes to Consolidated Financial Statements\" are incorporated in this \"Legal Proceedings\" section by reference .\n At July 31, 2025, there were approximately 5,917 shareholders of record of our common shares . We anticipate that we will continue to pay quarterly cash dividends in the future . The payment and amount of future dividends remain, however, within the discretion of our Board of Directors and will depend upon our future earnings, financial condition, capital requirements, and other factors .\n Investments are weighted on the basis of market capitalization at the beginning of each period and reinvestment of dividends . The S&P 500 Index and S.P 500 Healthcare Index investments are weighted based on the . end of each fiscal year through and including June 30, 2025, and reinvesting of dividends.\n Internal control over financial reporting may not prevent or detect misstatements . Internal controls deemed effective now may become inadequate in the future because of changes in conditions, or because compliance with policies or procedures has deteriorated or been circumvented . Internal Control-Integrated Framework issued by Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)\n Cardinal Health, Inc. maintained, in all material respects, effective internal control over financial reporting as of June 30, 2025, based on criteria established in Internal Control—Integrated Framework issued by Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria) We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB)\n A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles . We believe that our audit provides a reasonable basis for our opinion of the company's internal control of its finances .\n Internal control over financial reporting may not prevent or detect misstatements . Internal controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate . The financial position of the Company at June 30, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended June 30, 2025, are presented fairly .\n These financial statements are the responsibility of the Company's management . Our responsibility is to express an opinion on the Company’s financial statements based on our audits . We conducted our audits in accordance with the standards of the PCAOB . Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud .\n The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not providing a separate opinion . During fiscal 2025, there was no impairment recognized related to Navista & ION or Cardinal Health at-Home Solutions . The fair value estimates were sensitive to significant judgmental assumptions including the revenue growth rate, gross margin; distribution, selling, general and administrative expenses .\n To test the estimated fair values of Navista & ION and Cardinal Health at-Home Solutions, we performed audit procedures that included, among others, evaluating methodologies used; involving our valuation specialists to assist with our procedures related to the measurement of the fair values . For example, we tested controls over management’s review of significant judgmental assumptions, including the revenue growth rate; gross margin; distribution, selling, general and administrative expenses, and company-specific risk premium, among other assumptions .\n Cardinal Health, Inc.  reportedly reported financial statements of the Fiscal Years Ended June 30, 2025, 2024, 2024 and 2023 . Cardinal Health form 10-K: Cardinal Health’s federal finance statement of compound of comprehensive income loss and cash flow flows for the fiscal years ended June 30 25 25 and 2023 . Cardinal Health: Net earnings attributable to Cardinal Health attributable to noncontrolling interests: $1,569-$853-$1,561$852-$952\n The accompanying notes are an integral part of these consolidated statements . The financial statements follow the financial statements of Cardinal Health, Inc. 241. 241-245 per cent of the company’s net earnings and other noncontrolling interests . The company's current assets are $53,122,122 and $1,874,000 respectively .\n The accompanying notes are an integral part of these consolidated statements . Cardinal Health, Inc.  deficit: Preferred shares, without par value: preferred shares, Issued—preferred shares,  common shares,    -  Common shares in treasury, at cost:  premier shareholders’ depends $2,956-$2,917 Retained earnings .\n The accompanying notes are an integral part of these consolidated statements . The financial statements are presented in the form of a Form 10-K, a form of financial statements . They include net earnings, net of tax, employee stock plans and share repurchase program activity . The company paid $1,561 for each share and $2,917 for shares withheld for employee taxes .\n The accompanying notes are an integral part of these consolidated statements . Cash and equivalents at beginning of period: $5,133-$4,076 - $4,745 -  cash and equivalents at end of period; $3,874 - cash and entequipment acquisition of subsidiaries were acquired by Cardinal Health, Inc.\n Cardinal Health, Inc. provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices . References to “we,” “our” and similar pronouns in these consolidated financial statements are to Cardinal Health and its majority-owned or controlled subsidiaries, unless the context otherwise requires .\n The allowance for doubtful accounts includes reserves related to customer disputes and late fees billed to customers . An account is considered past due on the first day after its due date . The allowance includes intangible asset impairment, vendor reserves, loss contingencies (including product liability and self-insurance accruals) Actual amounts may differ from these estimated amounts .\n Finance notes receivable allowance for doubtful accounts were $.2.2 billion and $.3 billion at June 30, 2025 and 2024 . Credit risk can be affected by changes in reimbursement and other economic pressures impacting the healthcare industry . With respect to customers in the retail and healthcare sectors, such credit risk is limited due to the diversity of the customer base .\n CVS Health Corporation (\"CVS Health\") is our only customer that individually accounted for at least 10 percent of revenue and/or gross trade receivables in fiscal 2025 . In fiscal 2024, both CVS health and OptumRx collectively accounted for  10% of revenue . CVS has entered into agreements with group purchasing organizations (“GPOs”) which act as purchasing agents that negotiate vendor contracts on behalf of their members . Vizient, Inc. and Premier, Inc., are our two largest GPO member relationships in terms of revenue. Sales to members of these GPOs collectively account for \n At June 30, 2025 and 2024, inventories valued at LIFO cost were significantly in excess of the average cost value . Inventory at replacement cost determined using average cost method of inventory valuation . Inventory in GMPD segment and certain inventory in Pharma segment is stated at the lower of cost, using the first-in, first-out method or net realizable value .\n Inventories presented in the consolidated balance sheets are net of reserves for excess and obsolete inventory . An impairment assessment may be performed on the recoverability of the carrying amounts . We capitalize project costs relating to computer software developed or obtained for internal use when the activities related to the project reach the application stage. Costs that are associated with the preliminary stage activities, training, maintenance, and all other post-implementation stage activities are expensed as they are incurred .\n The amount of capitalized interest was immaterial for all periods presented . Interest on long-term projects is capitalized using a rate that approximates the weighted-average interest rate . The excess of the purchase price over the estimated fair value of the net assets acquired is recorded as goodwill . Property and equipment, at cost of $2,858 at June 30, 2025.\n Purchased goodwill and intangible assets with indefinite lives are not amortized, but instead are tested for impairment annually or when indicators of impairment exist . Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events, and circumstances to determine if it is more likely than not that an impairment exists .\n As of June 30, 2025, our reporting units are: Pharma (excluding Navista & ION and GIA), Navista, GIA, GMPD, Nuclear and Precision Health Solutions, OptiFreight®® Logistics, at-Home Solutions, and ADS. We use discount rates that are commensurate with the risks and uncertainty inherent in the respective reporting units and in our internally-developed forecasts. Actual results may differ from those used in our forecasts.\n We performed annual impairment testing in fiscal 2025, 2024, and 2023 for our reporting units, which included Navista & ION . The use of alternate estimates and assumptions or changes in the industry or peer groups could materially affect the determination of fair value for each reporting unit and potentially result in goodwill impairment . The impairment test for indefinite-lived intangibles other than goodwill involves assessing qualitative factors to determine if it is more likely than not that the fair value of the indefinite .\n Intangible assets with finite lives, primarily customer relationships; trademarks, trade names, and patents; and developed technology, are amortized using a combination of straight-line and accelerated methods based on the expected cash flows from the assets over their estimated useful lives . Actual results may differ from those used in our forecasts .\n In June 2024, we signed an agreement to sell the West Campus Dublin, Ohio office space . At that time, we met the criteria for the related assets to be classified as held for sale . During fiscal 2025, the purchase agreement was terminated . The related assets were reclassified as assets held for use . We evaluated and recognized an impairment during fiscal 2025 .\n Operating lease expense for operating lease assets is recognized on a straight-line basis over the lease term . Sublease income and related assets and cash flows are not material to the consolidated financial statements at or for the fiscal years ended June 30, 2025, 2024, and 2023 . Leases generally do not contain any material residual value guarantees or material restrictive covenants .\n At any given time, there are outstanding items in various stages of research and resolution . In determining appropriate reserves for areas of exposure with our vendors, we assess historical experience and current outstanding claims . We have established various levels of reserves based on the type of claim and status of review . The ultimate outcome of certain claims may be different than our original estimate and may require an adjustment .\n In February 2022, we and two other national distributors announced that each company had determined that a sufficient number of political subdivisions had agreed to participate in the previously disclosed National Opioid Settlement Agreement (the \"NOSA\") to settle the vast majority of the opioid lawsuits filed by states and local governmental entities . At June 30, 2025, we have a total of $56.56 million accrued for losses and legal defense costs, related to the IVC filter product liability lawsuits .\n The amount of ultimate loss may differ from these estimates . We recognize these estimated loss contingencies, income from favorable resolution of litigation, and certain defense costs in litigation (recoveries)/charges, net in our consolidated statements of earnings. idated balance sheets, which includes the $39.5 million in the qualified settlement fund. idant balance sheets .\n Historically, we have not, individually or in the aggregate, made payments under these indemnification obligations in any material amounts . In certain circumstances, we believe that existing insurance arrangements, subject to the general deduction and exclusion provisions, would cover portions of the liability . There were no material obligations at June 30, 2025 .\n Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position . The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement . For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits .\n We consolidate a VIE when we have the power to direct the activities that most significantly impact the VIE’s economic performance and the obligation to absorb losses or the right to receive benefits . The GIA VIEs do not have a material impact on our consolidated statements of earnings or statements of cash flows . The fair value of performance share units (\"PSUs\") is determined using a Monte Carlo valuation model .\n The compensation expense associated with nonvested PSUs is dependent on our periodic assessment of the probability of the performance goals being achieved . Compensation expense recognized for share-based awards is net of estimated forfeitures and is recognized ratably over the service period of the awards . All income tax effects are recognized in the consolidated statements of earnings as awards vest or are settled .\n The fair value of the vested GIA Units with no future service requirement are recorded as an assumed liability at the acquisition date . These GIA units contain forfeiture provisions ranging from 36 to 60 months . The unit holders must stay employed with the physician practice managed by GIA in order to retain all of the granted units during the forfeiture period .\n Logistics revenue is related to shipping, freight management, and logistics management services . We recognize at a point in time when title transfers to customers and we have no further obligation to provide services related to such merchandise . We are generally the principal in a transaction, therefore our revenue is primarily recorded on a gross basis .\n We accrue for estimated sales returns and allowances at the time of sale based upon historical customer return trends, margin rates, and processing costs . Our accrual for sales returns is reflected as  a reduction of revenue and cost of products sold for the sales price and cost, respectively . The net impact on net earnings in the consolidated statements of earnings was immaterial in fiscal 2025, 2024, and 2023 . We generally do not accept non-merchantable pharmaceutical product returns from our customers .\n Shipping and handling costs are primarily included in SG&A expenses in our consolidated statements of earnings . Restructuring activities are programs that are not part of the ongoing operations of our underlying business, such as divestitures, closing and consolidating facilities, changing the way we manufacture or distribute our products . Employee severance costs are not incurred in connection with a restructuring activity .\n Transaction costs are incurred during the initial evaluation of a potential acquisition and primarily relate to costs to analyze, negotiate, and consummate the transaction . Integration costs relate to activities required to combine the operations of an acquired enterprise into our operations . Foreign currency transaction gains and losses for the period are included in the consolidated statements of earnings in the respective financial statement line item .\n All changes in fair value are recognized in net earnings or shareholders’ equity through AOCI, net of tax . Any contract not designated as a hedge, or so designated but ineffective, is adjusted to fair value . Interest payments received from the cross-currency swap are excluded from the net investment hedge effectiveness assessment .\n FASB issued Accounting Standards Update (\"ASU\") 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . The Company adopted the new guidance in our fiscal 2025 Form 10-K . The new standard did not have an impact on the company's consolidated financial statements but required additional disclosures .\n In November 2024, the FASB issued ASU 2024-03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) This guidance will be effective for us in our fiscal 2026 Form 10-K and should be applied on a prospective basis, with retrospective application permitted . We are evaluating the impact of adoption of this guidance on our disclosures .\n GI Alliance (\"GIA\") completed the acquisition of a 73.73 percent ownership interest in GIA, a gastroenterology management services organization, for a purchase price of approximately $2.8 billion in cash, subject to certain adjustments . GIA has the ability to exercise a call right to purchase up to 100 percent of the remaining outstanding interests .\n The portion of ION net earnings attributable to noncontrolling interest holders is reported as a reduction to net earnings in the consolidated statements of earnings . The acquisition was funded with available cash on hand . The allocation of the purchase price for the acquisition of Urology America, ADS, GIA, and ION are not yet finalized .\n The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as of the acquisition date for Urology America, ADS, GIA, ION, and Specialty Networks . The purchase prices are also subject to adjustment based on working capital requirements as set forth in the acquisition agreement . We complete the valuation analysis of these acquisitions .\n The valuation of identifiable intangible assets utilizes significant unobservable inputs and thus represents a Level 3 nonrecurring fair value measurement . The discount rates used to arrive at the present values for Urology America, ADS, GIA, ION, and Specialty Networks are based on their internal rates of return and uncertainty in the cash flow projections, which is reflective of market participant assumptions .\n The fair value of the GIA Units was determined using a discount rate of  9.5% and an estimated weighted average service period of  two years . The allocation of the fair value  of assets acquired and liabilities assumed for the Specialty Networks acquisition was finalized during fiscal 2025 . There were no significant adjustments to the allocation  of the . fair value . of the non-compete intangibles acquired from GIA were determined by applying the differential cash flow method .\n The divestiture of the Outcomes™ business does not meet the criteria to be classified as discontinued . Restructuring and employee severance costs in fiscal 2025, 2024, and 2023 include costs related to certain initiatives to rationalize our manufacturing operations . Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs, and retention bonuses incurred during transition periods .\n The following table summarizes the changes in the carrying amount of goodwill for the two reportable segments and the remaining operating segments, included in Other and in total . At June 30, 2025 and 2024, the GMPD segment accumulated goodwill impairment loss was $5.4 billion . The remaining operating segment, Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight and Logistics Logistics, increased goodwill . d to the divestiture of the Cordis business .\n During fiscal 2023, GMPD had cumulative pre-tax impairment charges of $1.2.2 billion . GMPD goodwill was fully impaired during the third quarter of fiscal 2024 . The increase in the Other segment goodwill is due to the ADS acquisition that occurred during fiscal 2025 . Substantially all of the goodwill recorded is expected to be nondeductible for income tax purposes .\n The increase in definite-life intangibles is primarily due to the ADS, GIA, and ION acquisitions . The estimated annual amortization for intangible assets for fiscal 2026 through 2030 is as follows: $395,000, $374,000 and $281,000 for fiscal 2025, 2024, and 2023 .\n The following table summarizes supplemental cash flow information related to leases as of June 30 . The company's right-of-use asset and liability balances are primarily due to acquisitions . Finance leases are included in property and equipment, net, current portion of long-term obligations and other short-term borrowings, less current portion in our consolidated balance sheets .\n The following table summarizes long-term obligations and other short-term borrowings at June 30 . The 7.0% Debentures represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing unsecured and unsubordinated indebtedness .\n During fiscal 2025, Cardinal Health issued additional debt to fund a portion of the consideration payable in connection with the GIA and ADS acquisitions . These notes are effectively subordinated to the liabilities of our subsidiaries . None of these obligations are subject to a sinking fund and the Allegiance obligations are not redeemable prior to maturity . All short-term time deposits related to the debt issuance in fiscal 2024 have matured .\n The proceeds of the notes issued, net of discounts, premiums, and debt issuance costs were $1.14.14 billion . During fiscal 2024, we repaid the full principal of $750.7 million of the 3.079% Notes due 2024 at maturity . Other sources of liquidity include a $3.0-billion commercial paper program backed by a $2.0 billion revolving credit facility that expires in February 2028 .\n In February 2023, we extended our $2.0 billion revolving credit facility through February 25, 2028 . In September 2022, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (“CHF”) through September 30, 2025 . Each of CHF and CH-23 Funding is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy its respective creditors .\n At June 30, 2025, Cardinal Health had a daily maximum amount outstanding under commercial paper and committed receivables programs of $70533 million . At June 2025, we were in compliance with this financial covenant of no more than 3.75-to-1. erage ratio . We established Red Oak Sourcing, LLC, a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years .\n Distributors challenged the OSA as unconstitutional . The New York Appellate Division held that the 2017 assessment was unconstitutionally retroactive . In fiscal 2025, both parties agreed to a settlement which will result in a refund of the portion we paid for calendar year 2017 . The refund will be recognized upon receipt of the settlement .\n We have been named from time to time in qui tam actions initiated by private third parties . Private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful . We receive subpoenas or requests for information relating to our business or to the business of a customer, supplier, or other industry participants .\n We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries/charges) The amount of ultimate loss may differ from these estimates . Loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur . We regularly review contingencies to determine whether our accruals and related disclosures are adequate .\n Cardinal Health has settled the vast majority lawsuits and claims brought by states and political subdivisions related to the distribution of opioid pain medications . The vast majority of the opioid lawsuits filed by states, local governmental entities and payments related to Cardinal Health have been settled . The company has paid the Settling Governmental Entities approximately $2.2 billion through July 2025 .\n Distributors have engaged a third-party vendor to act as a clearinghouse for data aggregation and reporting, which distributors will fund until 2032 . NOSA does not address claims by private parties, which includes unions, other health and welfare funds, hospital systems and other healthcare providers, businesses, and individuals alleging personal injury .\n Distributors is involved in ongoing legal proceedings with insurers related to their obligations to reimburse us for defense and indemnity costs in connection with lawsuits described above . Department of Justice Civil Investigative Demand focused on potential violations of the Anti-Kickback Statute and False Claims Act in 2022 transaction in which we purchased a minority ownership interest in a rheumatology managed services organization and group purchasing organization .\n The divestiture of the Cordis business did not include product liability related to the IVC filters in the U.S. and Canada, which we retained . In April 2023, we executed a settlement agreement that, if certain conditions are satisfied, will resolve approximately  around $4,375 claims for $275 million . At June 30, 2025, we have a total of $56 million accrued for losses and legal defense costs .\n Pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs . The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania . We recognized income for net recoveries in class action antitrust lawsuits in which we were a class member or plaintiff .\n In fiscal 2024 and 2023, we recognized cumulative pre-tax goodwill impairment charges of $675.675.million, $.2.2 billion, and $.39 billion related to GMPD . Net tax benefits related to these charges were $.58 million and $.92 million during fiscal 2024 and 2023 . The effective tax rate for fiscal 2025 were non-deductible share based compensation costs for The Specialty Alliance . The income tax rate was   reformulated to reflect the tax impact of the Foreign-Derived Intangible Intangible Income (\"FDII\") deduction offset by Global Intangible Low-Taxed Income (\"GILTI\")\n Cardinal Health's effective tax rate for fiscal 2024 and 2023 was  preformed in the form 10-K. in the effective tax rates for fiscal 2023 and fiscal 2024 . The company recorded an immaterial amount of income tax expense in its consolidated financial statements in fiscal 2025 .\n At June 30, 2025, we had gross federal, state, and international loss and credit carryforwards of $.154 million, $.6 billion, and $.1 billion, respectively, the tax effect of which is an aggregate deferred tax asset of $386.386 million . The valuation allowance for deferred income tax assets, after netting by taxing jurisdiction and for uncertain tax positions, would reduce income tax expense .\n The remaining unrecognized tax benefits relate to tax positions for which ultimate deductibility is highly certain but for which there is uncertainty as to the timing of such deductibility . Recognition of these tax benefits would not affect our effective tax rate . We expect any changes to the unrecognized benefits in the next 12 months will not be material .\n At June 30, 2025, 2024, and 2023, we had $.65.7 billion in interest and penalties related to unrecognized tax benefits in the provision for income taxes . As a result of our IRS audit settlements and carryback claim, an immaterial amount of interest was recorded . We operate in a complex multinational tax environment and are subject to tax treaty arrangements and transfer pricing guidelines .\n The fair value of interest rate swaps, foreign currency contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance  risk, and using discount rates appropriate for the respective maturities . The fair . value of the GIA Units is determined using the discounted cash flow method .\n The primary risks managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk . The majority of our derivative instruments are designated as hedging instruments . We only enter into derivative instruments with major financial institutions that are rated investment grade or better . We do not use derivative instruments for trading or speculative purposes .\n Cardinal Health is exposed to changes in the price of certain commodities . Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations . We enter into derivative contracts when possible to  manage the price risk associated with certain forecasted purchases .\n During fiscal 2025, 2024, and 2023 there were  no gains or losses recorded to interest expense as changes in the market value of our derivative instruments offset changes in market value . The gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt . The resulting resulting gain and loss is recorded in interest expense, net in the consolidated statements of earnings .\n At June 30, 2025 and 2024, Cardinal Health held contracts to hedge probable, but not firmly committed, revenue and expenses . The principal currencies hedged are the Canadian dollar, Mexican peso, Chinese renminbi, Thai baht, and Philippine peso . The gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction .\n We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries . To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments . In September 2023, we terminated the ¥39billion ($39billion) of foreign currency swaps entered into in Januu . In February 2025, we entered into €100.000 million ($107.000) of cross currency swaps maturing in February 2027 .\n In January 2023, we entered into ¥.19 billion ($150.150%) cross-currency swaps maturing in September 2025 and ¥. ary 2023 and received net settlement in cash of $.28 million . These were recorded in proceeds from net investment hedge terminations in our consolidated statements of cash flows . Gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale of the underlying net investments .\n The principal currencies managed through foreign currency contracts are the Canadian dollar, euro, Chinese renminbi, Mexican peso, and Brazilian real . The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net in the consolidated statements of earnings .\n The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement . At June 30, 2025 and 2024, authorized capital shares consisted of  referred capital shares . Holders of common shares are entitled to share equally in any dividends declared by the Board of Directors .\n Only Class A common shares were outstanding at June 30, 2025 and 2024 . The holders of Class B common shares are entitled to one-fifth of one vote per share on proposals presented to shareholders for vote . We repurchased $2.5 billion of our common shares, in the aggregate, through share repurchase programs during fiscal 2025,  2024, and 2023, as described below .\n Cardinal Health repurchases began on September 14, 2022 and concluded on August 16, 2023 . Cardinal Health, Inc. repurchased 4.6 million common shares under multiple ASR programs with average prices paid per common share of $73.36%-36%, $77.50%-$77.27%- and $87.18%- respectively .\n The potentially dilutive employee stock options, restricted share units, and performance share units that were anti-dilutive were immaterial . Cardinal Health operates under two reportable segments: Pharma and GMPD . The remaining remaining operating segments are included in Other, which is comprised of Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Solutions .\n The remaining non-reportable operating segments included in Other are Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight®™ Logistics . These operating segments respectively operate nuclear pharmacies and distribute medical products to patients' homes in the United States, Canada, Europe, Asia, and other markets .\n The Company’s Chief Executive Officer, the chief operating decision maker (\"CODM\"), evaluates segment performance based on segment profit . Segment profit is segment revenue less segment cost of products sold, less segment distribution, selling, general, and administrative expenses . Corporate expenses are allocated to the operating segments based on headcount, level of benefit provided and other ratable allocation methodologies .\n Certain investment spending, certain portions of enterprise-wide incentive compensation, and other spending are not allocated to the segments . Investment spending generally includes the first-year spend for certain projects that require incremental investments . The following tables present revenue, expenses, and segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate .\n The following tables present depreciation and amortization and additions to property and equipment for the two reportable segments and the remaining operating segments, included in Other, and Corporate, at June 30 . The following table presents total assets for the . reportable . segments . The Cardinal Health, Inc. stock incentive plans (collectively, the “Plans for the ‘Plans’) are based on Cardinal Health’s share-based compensation plans .\n Cardinal Health, Inc. 2021 Long-Term Incentive Plan (\"2021 LTIP\") Under the 2021 LTIP's fungible share counting provisions, stock options are counted against the plan as one share for every share issued . At June 30, 2025,  around 15.5 million shares remain available for future grants under the plan .\n The Company's share-based compensation expense is a reconciling adjustment between net income and net cash provided by operating activities for all periods presented . The following table summarizes all transactions related to restricted share units under the Plans . Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards .\n Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards . lth Care Index, vested shares may range from zero-zero-to-240 percent of the target award amount . The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts)\n GIA has entered into a definitive agreement to acquire Solaris Health, a urology MSO, for a purchase price of approximately $1.9 billion in cash, subject to certain adjustments . The liability and associated future expenses may vary based on the changes in the estimated fair value of the GIA Units as of June 30, 2025 .\n Solaris Health includes more than 750 providers across more than 250 practice locations in 14 states . The company intends to finance the announced transaction with a combination of cash on hand and cash proceeds from new debt financing . The transaction is subject to the satisfaction of customary closing conditions, including receipt of required physician and regulatory approvals .\n The following is a list of our executive officers . Jason M. Hollar has served as Chief Executive Officer since September 2022 . Aaron E. Alt was Chief Financial Officer of Sears Holding Corporation (\"Sears\") from October 2016 to April 2017 . Jason Hollar served as CEO of Cardinal Health from May 2020 to August 2022 .\n Cardinal Health has adopted  Standards of Business Conduct Guidelines that apply to all of our directors, officers, and employees . The full text of the guidelines is posted on our website at www.cardinalhealth.com under “About Us — Ethics and Compliance’s website . Any waiver of the  Guidelines must be approved by the Risk Oversight Committe .\n The other information called for by Item 10 of Form 10-K is incorporated by reference to our Definitive Proxy Statement (which will be filed with the SEC pursuant to Regulation 14A under the Exchange Act) under the captions “Corporate Governance” and “Share Ownership Information” The following financial statements are included in the \"Financial Statements\" section of this report .\n The following Supplemental Schedule is included in this report: (a) (b) (B) (C) (A)) All other schedules not listed above have been omitted as not applicable or because the required information is . included in the Consolidated Financial Statements or in the Notes . The following supplemental Schedule includes the following two schedules: (b), (c) (d) (g) (G)) (e) (i)\n The C.U.S. Department of Health, Inc., as issuer, and The Bank of New York Mellon Trust Company, N.A., as trustee (incorporated by reference to Exhibit 4.2 to Cardinal Health’s Current Report on Form 8-K filed on Nov. y 22, 2013, File No. 1-11373)\n Cardinal Health, Inc. urrent Report on Form 8-K filed on February 20, 2024, File No. 1-11373 . Exhibits: 5.125% Senior Notes due 2029, 5.450% Senior Note due 2034 and 5.2.18.18% Notes due . Cardinal Health  Fiscal 2025 Form 10-K: Fiscal 2025 .\n Cardinal Health, Inc. 2021 Long-Term Incentive Plan effective as of January 29, 2024 (as amended, the \"2021 LTIP\") (incorporated by reference to Exhibit 10.1.1 to Cardinal Health’s Quarterly Report on Form 10-Q filed on May 2, 2024, File No. 1-11373)\n First Amendment to the Cardinal Health, Inc. 2011 Long-Term Incentive Plan effective as of January 29, 2024 (incorporated by reference to Exhibit 10.1.1 to Cardinal Health’s Current Report on Form 8-K/A filed on November 9, 2021, File No. 1-11373)\n Amended Cardinal Health, Inc. 2011 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.2.2 to Cardinal Health's Annual Report on Form 10-K for the fiscal year end June 30, 2017, File No. 1-11373) The plan includes the Cardinal Health Inc. 2007 Nonemployee Directors Equity Incenture Plan .\n The Cardinal Health, Inc. 2007 Nonemployee Directors Equity Incentive Plan (incorporated by reference to Exhibit 10.2.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2007, File No. 1-11373) Exhibits: Cardinal Health Deferred Compensation Plan, Amended and Restated effective January 1, 2020, and Senior Executive Severance Plan .\n The Cardinal Health, Inc. ior Executive Severance Plan (incorporated by reference to Exhibit 10.6.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2019, File No. 1-11373) The plan includes third Amendment to the Cardinal Health .\n Cardinal Health, Inc. d on December 19, 2022, File No. 1-11373*: Confidentiality and Business Protection Agreement, effective as of August 16, 2019, and Stephen M. Mason. Mason (incorporated by reference to Exhibit 10.9.2 to Cardinal Health's Current Report on Form 8-K filed on March 19, 2020)\n Third Amendment to Issuing and Paying Agency Agreement, dated September 15, 2017, between Cardinal Health, Inc. and The Bank of New York (incorporated by reference to Exhibit 10.2 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)\n Exhibits: Commercial Paper Dealer Agreement between Cardinal Health, Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated, f/k/a Banc of America Securities LLC, effective as of December 1, 2016, and effective December 31, 2016 . Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2006, File No. 1-11373 .\n Commercial Paper Dealer Agreement between Cardinal Health, Inc. and Wells Fargo Securities, LLC, effective as of December 1, 2016 (incorporated by reference to Exhibit 10.5 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2016, File No. 1-11373)\n Commercial Paper Dealer Agreement between Cardinal Health, Inc. and SunTrust Robinson Humphrey, Inc., effective as of December 1, 2016 . Third Amended and Restated Five-Year Credit Agreement, dated as of February 27, 2023 (incorporated by reference to Exhibit 10.2 to Cardinal Health’s Current Report on Form 8-K filed on April 21, 2009, File No. 1-11373)\n Some of the keynotes include the Fourth Amended and Restated Receivables Purchase Agreement, dated as of November 1, 2013, and Fourth Amendment and Joinder, dated September 30, 2019 . Some of these amendments are related to Cardinal Health’s Current Report on Form 8-K filed on August 31, 2017, and Sept. 30, 2018 .\n Amended and Restated Performance Guaranty, dated as of November 14, 2016, executed by Cardinal Health, Inc. in favor of Cardinal Health Funding, LLC (incorporated by reference to Exhibit 10.5.1 to Cardinal Health’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, File No. 1-11373)\n Cardinal Health’s Annual Report on Form 10-K for the fiscal year ended June 30, 2012, File No. 1-11373 . Cardinal Health, Inc. (incorporated by reference to Exhibit 10.1 to Cardinal Health's Form 8-K filed on September 4, 2009, File . No. 15.2: First Amendment to Tax Matters Agreement, dated as of May 28, 2012 .\n ine XBRL Taxonomy Extension Calculation Linkbase Document: Inline XBLS Taxonomy Definition, Exhibit 101 and Exhibit 101 . Exhibit 101 is in response to Inline's 2025 Proxy Statement under the captions “Corporate Governance” and “Executive Compere’s’ Executive Compereship”\n The information called for by Item 12 of Form 10-K is incorporated by reference to our 2025 Proxy Statement under the captions \"Executive Compensation\" and \"Share Ownership Information\" The registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 12, 2025 .\n y                       Nancy Killefer.                                                           ROBERT W. MUSSLEWHITE                                                                                                   Robert W. Musslewhite/s. Musslewhite.                                                                                    Catherine A. Mundkur                                       apologetic ‚��™™™/s/                 Cabinetarians receive financial benefits from Cardinal Health Department of the U.S."
}